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OBJECTIVES We studied whether left ventricular mass in athletes associates with polymorphisms in genes
encoding components of the renin–angiotensin system.
BACKGROUND Adaptive left ventricular hypertrophy is a feature of the athlete’s heart. However, similarly
training athletes develop left ventricular mass to a different extent, suggesting that genetic
factors may modulate heart size.
METHODS We measured left ventricular mass by echocardiography in 50 male and 30 female elite
endurance athletes aged 25 6 4 (mean 6 SD) years. Deoxyribonucleic acid samples were
prepared for genotyping of angiotensinogen (AGT) gene M235T polymorphism,
angiotensin-converting enzyme (ACE) gene insertion/deletion (I/D) polymorphism and
angiotensin II type 1 receptor (AT1) gene A1166C polymorphism.
RESULTS The AGT gene M235T genotypes were significantly associated with left ventricular mass
independently of blood pressure in both genders (p 5 0.0036 for pooled data). TT
homozygotes had greater mass compared with MM homozygotes in both men (147 6 12 g/m
vs. 132 6 15 g/m, p 5 0.032) and women (121 6 12 g/m vs. 101 6 13 g/m, p 5 0.019).
There was a gender difference in the relation between myocardial mass and AGT genotype,
MT heterozygotes resembling MM homozygotes among women and TT homozygotes
among men. The other studied gene polymorphisms were not associated with left ventricular
mass.
CONCLUSIONS Angiotensinogen gene M235T polymorphism is associated with the variability in left
ventricular hypertrophy induced by endurance training, with athletes homozygous for the T
allele having the largest hearts. We found no association between ACE gene I/D or AT1
gene A1166C polymorphisms and left ventricular mass. (J Am Coll Cardiol 1999;34:494–9)
© 1999 by the American College of Cardiology
Cardiac hypertrophy usually follows an increase in workload
imposed on the heart. In this process, mechanical, neural
and endocrine mechanisms are important. However, indi-
vidual myocardial responses to the workload are variable; for
instance, there is a poor correlation between blood pressure
and left ventricular (LV) hypertrophy in individual study
participants (1). It has been observed that endurance ath-
letes with similar training habits develop increased LV mass
to different extents and that the amount of training accounts
for only 11% of the variability in their LV mass (2). These
findings suggest the potential importance of genetic factors
in determining the heart size.
In endurance athletes, LV mass is on the average 45%
greater than in matched control subjects (3). We hypothe-
sized that a homogenous study population exposed to a
strong, long-lasting and similar environmental myocardial
growth stimulus, as is the case in young endurance athletes,
could be an appropriate group for studying the possible
genotypic modulation of increased LV mass. Recent exper-
imental and clinical studies have suggested that the local
cardiac renin–angiotensin system (RAS) may modulate
cardiac growth. Synthesis of several important RAS com-
ponents, including angiotensinogen (AGT), angiotensin-
converting enzyme (ACE) and angiotensin II type 1 recep-
tor (AT1), has been shown to take place in myocardium and
to be up-regulated during myocardial growth (4–6). We
analyzed the associations of adaptive LV hypertrophy with
three common allelic variations in these RAS components,
namely the ACE gene insertion/deletion (I/D) polymor-
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phism (7–9), the AGT gene Met 235Thr polymorphism
(9–11) and the AT1 gene A1166C polymorphism (12,13),
chosen because of their suggested association with LV
hypertrophy in selected clinical materials.
METHODS
Study population. We studied 80 elite endurance athletes
from the Finnish national teams, 50 men and 30 women,
aged 25 6 4 (mean 6 SD) years. The study group included
long-distance runners, orienteers and cross-country skiers
and triathlonists, all of whom gave their written informed
consent for the study. Based on their training diaries, the
subjects self-reported in the questionnaire their mean
weekly volume (hours and minutes/week) of effective train-
ing including competitions. Most of the training was
endurance training. None of the subjects used anabolic
steroids or other drugs known to cause cardiac muscle
hypertrophy. All participated in echocardiography to study
the LV mass, geometry and filling. Blood pressure was
obtained sphygmomanometrically in the supine position
after 5 min rest. Peripheral blood was drawn and frozen for
subsequent preparation of deoxyribonucleic acid for geno-
typic assays.
Echocardiography. Echocardiographic and Doppler stud-
ies were performed with an Acuson 128 instrument and
V319 2.5- to 3.5-mHz transducer. To avoid including
trabeculations (often prominent in an athlete’s heart) in the
wall thickness measurements, an integrated M-mode and
two-dimensional study was done to determine interventric-
ular septal and LV posterior wall thickness and end-diastolic
cavity dimension as described in detail earlier (2). Left
ventricular mass was calculated using the formula by De-
vereux (14):
mass 5 0.8z@1.04z~septal thickness 1 end-diastolic diameter
1 posterior wall thickness!3 2 end-diastolic diameter3#
1 0.6 g.
Left ventricular mass was indexed to height. Concentric-
ity of the myocardium was estimated by calculating the
relative wall thickness using the formula:
relative wall thickness 5 ~septal thickness
1 posterior wall thickness!/LV end-diastolic diameter.
Measurements of LV diastolic filling velocities were
obtained in an apical four-chamber view by positioning the
pulsed Doppler volume sample about 1 cm below the mitral
annulus. Early peak flow velocity (E) and peak atrial flow
velocity (A) were measured and the ratio E/A calculated. All
echocardiographic measurements were made by the same
observer between 8:00 and 10:00 AM after a light breakfast,
and obtained directly from the screen monitor with the aid
of calipers and the instrument trackball.
Determination of AGT, ACE and AT1 genotypes. The
ACE I/D polymorphism was determined according to
Rigat et al. (15), and supplemented with confirmatory assays
as suggested by Shanmugan et al. (16). The M235T
polymorphism of the AGT gene and the A1166C polymor-
phism of the AT1 gene were assayed using the solid-phase
minisequencing method (17). In the case of M235T, a
polymerase chain reaction (PCR) product spanning the
polymorphic site was generated using the biotinylated
primer 59-TCT GGA CTT CAC AGA ACT GGA T-39
and the primer 59-CTT GGA AGT GGA CGT AGG
TGT-39. The PCR products were captured in streptavidin-
coated microtitration plate wells and rendered single
stranded. The polymorphic nucleotide was detected in the
captured deoxyribonucleic acid strand by extension of the
“minisequencing” primer 59-TGC TGT CCA CAC TGG
CTC CC-39 with a single 3H-labeled deoxyadenosine
triphosphate or deoxycytidine triphosphate. In the case of
the A1166C polymorphism of the AT1 gene, a PCR
product spanning the polymorphic site was generated using
the biotinylated primer 59-AAG CTT TTG TTC AGA
GCT TTA G-39 and the primer 59-GTT CGA AAC
CTG TCC ATA AAG-39, whereafter the primer 59-CAC
TTC ACT ACC AAA TGA GC-39 was used as the
“minisequencing” primer (17).
Statistical methods. We tested our a priori hypothesis that
polymorphisms in genes encoding the cascade of RAS
(ACE I/D polymorphism, AGT M235T polymorphism
and AT1 A1166C polymorphism) and LV mass were
associated, using separate analysis of covariance (ANCOVA)
models for each of the gene polymorphisms. Our basic
ANCOVA models controlled for gender (between factor) as
well as for age (covariate). All of our participants had
competed in competitive sports since childhood; using age
as covariate adjusted for years of training. Fisher least
significant difference procedure test was used for post hoc
multiple comparisons. For hypothesis testing the level of
statistical significance was set at p , 0.05. Different analysis
of variance and ANCOVA models as well as linear regres-
sion analysis were used to characterize in more detail the
clinical significance of the statistically significant findings
that supported the hypotheses. All analyses were performed
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
AGT 5 angiotensinogen
ANCOVA 5 analysis of covariance
AT1 5 angiotensin II type 1 receptor
I/D 5 insertion/deletion
LV 5 left ventricular
PCR 5 polymerase chain reaction
RAS 5 renin–angiotensin system
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with the Statistica statistical package for Windows (Release
5, StatSoft, Tulsa, Oklahoma, 1995).
RESULTS
Characteristics of male and female athletes. Characteris-
tics of the athletes and data on the echocardiographic
measurements in men and women are summarized in Table
1. On average, indexed LV mass was 36% greater in male
(140 6 17 g/m) than in female (104 6 16 g/m) athletes. For
comparison, LV mass measured by the same observer and
method was 93 6 20 g/m in 15 age-matched sedentary men
(2) and 68 6 10 g/m in 15 age-matched sedentary women.
Frequencies of RAS gene genotypes. The frequencies of
the different genotypes for the three gene polymorphisms
examined are given in Table 2. All genotypic proportions
were in Hardy–Weinberg equilibrium. In the whole sample,
the ACE gene D and I allele frequencies were 54% and
46%, and the AGT gene M and T allele frequencies were
56% and 44%. These numbers do not differ significantly
from those found among 523 randomly selected Finnish
individuals (18). The A and C allele frequencies for the
AT1 polymorphism were 76% and 24%, respectively.
Association of AGT genotype with LV mass. There was
a significant association between the AGT genotype and
LV mass in both male and female athletes (p 5 0.0036 for
pooled data) (Table 3, Fig. 1). This association was mostly
due to differences in LV wall thicknesses (Table 4). As
analyzed by a post hoc least significant difference test,
subjects homozygous for the T allele had more hypertrophy
than those homozygous for the M allele (p 5 0.0013); this
finding was significant in both male (p 5 0.039) and female
(p 5 0.019) athletes. There was a gender difference in the
heterozygotes; MT men had a greater (p 5 0.021) LV mass
compared with the MM homozygotes but did not differ
significantly from TT homozygotes, whereas MT women
differed significantly (p 5 0.0038) only from the TT and
not from MM homozygotes (Table 3). When the analyses
were repeated with systolic or diastolic blood pressure as
covariate, the association between AGT genotypes and LV
mass did not weaken. Relative wall thickness did not
associate significantly with AGT genotypes, although
greater myocardial mass was associated with a more con-
Table 1. Characteristics of Endurance Athletes
Men (n 5 50) Women (n 5 30) p
Subject characteristic
Age (yr) 24.7 6 3.6 24.8 6 4.1 NS
Height (cm) 182 6 7 169 6 7 ,0.001
Weight (kg) 69 6 7 58 6 6 ,0.001
Body mass index (kg/m2) 20.8 6 1.5 20.2 6 1.8 NS
Heart rate (beats/min) 49 6 7 51 6 10 NS
Training (h/week) 10.3 6 2.0 9.7 6 2.2 NS
Systolic blood pressure (mm Hg) 129 6 12 120 6 9 ,0.001
Diastolic blood pressure (mm Hg) 74 6 10 75 6 9 NS
Echocardiographic left ventricular data
End-diastolic diameter (mm) 54.6 6 3.0 50.8 6 3.0 ,0.001
Septum (mm) 11.9 6 1.0 9.6 6 0.8 ,0.001
Posterior wall (mm) 11.1 6 1.0 9.4 6 1.0 ,0.001
Length (mm) 100 6 7 90 6 5 ,0.001
Mass (g) 255 6 32 176 6 29 ,0.001
Mass/height (g/m) 140 6 17 104 6 16 ,0.001
Relative wall thickness 0.42 6 0.05 0.37 6 0.04 ,0.001
Filling velocity index (E/A) 2.5 6 0.7 2.3 6 0.5 NS
Numbers are mean 6 SD.
E/A 5 early peak flow velocity/peak atrial flow velocity.





of SubjectsMM MT TT
AGT
Number 24 (30%) 41 (52%) 14 (18%) 79*
Male/female 17/7 24/17 8/6 49/30
DD DI II
ACE
Number 24 (30%) 38 (47.5%) 18 (22.5%) 80
Male/female 15/9 23/15 12/6 50/30
AA AC CC
AT1
Number 45 (58.5%) 27 (35%) 5 (6.5%) 77*
Male/female 30/15 17/10 1/4 48/29
*For technical reasons, angiotensinogen (AGT) genotype could not be determined in
one subject and angiotensin II type 1 receptor (AT1) genotype in three subjects.
ACE 5 angiotensin-converting enzyme.
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centric myocardial geometry (r 5 0.55, p , 0.0001 for
pooled data). Left ventricular filling velocities were not
affected by the AGT gene polymorphism. There were no
differences in body characteristics, volume of training or
blood pressures between the athletes with different AGT
genotypes (Table 4).
According to linear regression analysis, gender alone
explained 60% of the variation in indexed LV mass. When
men and women were considered separately, age and vol-
ume of training (mean training hours/week during the year
before the examination) combined explained 9% and 15% of
this variability, respectively. When AGT polymorphism was
added to the model, the cumulative explanation rate in-
creased by 13% (to 22%) in men and by 20% (to 35%) in
women. Adding body mass index to the model did not
significantly increase the explanation rate, obviously because
it was low in all athletes.
Associations of the ACE and AT1 genotypes. Because
only one man and four women had the AT1 gene CC
homozygote, we compared AA homozygotes with the
combined group of AC heterozygotes and CC homozy-
gotes. Left ventricular mass, geometry or filling were not
associated with the ACE or AT1 genotype (Table 3).
DISCUSSION
The novel result in this cross-sectional study was the strong
association of adaptive LV hypertrophy with AGT gene
M235T polymorphism. The finding was consistent in both
men and women athletes, with those homozygous for the T
allele having the greatest LV mass. In contrast, the ACE
gene I/D genotypes and the AT1 gene A1166C genotypes
were not significantly associated with LV mass.
Angiotensinogen polymorphism and LV hypertrophy.
The M235T polymorphism of the human AGT gene was
initially suggested to be associated with variation of serum
AGT concentration and risk of essential hypertension (19).
Subsequent studies have produced contradictory findings
(for review, see Corvol and Jeunemaitre [6]). A large survey
in Finland failed to demonstrate any association between
M235T polymorphism and elevated blood pressure (18).
In a heterogenous study population of hospitalized pa-
tients in Japan, subjects with the TT genotype were found
to have a significantly greater LV mass compared with those
with the M allele (10). In contrast, the AGT genotypes
were not associated with cardiac dimensions in a twin study
(11). In a recent large study of Finnish hypertensive and
control subjects, Kauma et al. did not find a significant
association between AGT or ACE genotypes and LV mass,
although in control men there was a clear tendency to
greater ventricular mass in the TT genotype (9).
The strong physiologic stimulus to myocardial growth in
our study subjects had caused an average increase in the LV
mass of 50% in male and 53% in female athletes, compared
with nonathletic age-matched subjects. It is reasonable to
claim that these circumstances would effectively unmask any
genetically determined modulating mechanisms. In contrast
to many earlier studies involving heterogenous study popu-
lations with multiple environmental and biologic influences
on myocardial mass, our study group was healthy and
normotensive, racially uniform, had a low body mass index
and most important, all had markedly increased LV mass.
Gender was the most important variable affecting cardiac
mass, explaining 60% of its variation. However, LV mass in
MM homozygotes differed from that in TT homozygotes in
both male (by 11%) and female athletes (by 20%). Interest-
ingly, there was a clear gender difference in the relation
between myocardial mass and AGT genotype, MT het-
erozygotes resembling MM homozygotes among women
and TT homozygotes among men. Thus our results suggest
Figure 1. Left ventricular mass in endurance athletes with different
genotypes of angiotensinogen (AGT) gene M235T polymor-
phism. Solid squares 5 mean; boxes 5 6SE; error bars 5 95%
confidence intervals.




F pMM MT TT
AGT
Men 132 6 15 144 6 18 147 6 12 3.72 0.032
Women 101 6 13 99 6 15 121 6 12 5.42 0.011
All* 123 6 20 126 6 28 136 6 17 6.10 0.0036
DD DI II
ACE
Men 145 6 18 137 6 15 141 6 18 0.28 0.76
Women 103 6 17 106 6 17 100 6 17 0.34 0.71
All* 129 6 27 125 6 22 127 6 27 0.11 0.90
AA AC or CC
AT1
Men 143 6 17 135 6 16 1.79 0.19
Women 102 6 16 105 6 17 0.19 0.66
All* 130 6 26 122 6 22 0.34 0.56
*Gender and genotype as between-group factors. Abbreviations as in Table 2.
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that sex hormones may affect myocardial growth differently,
depending on the number of T alleles the individual is
carrying.
Other polymorphisms and LV hypertrophy. We found
no significant associations between the ACE I/D polymor-
phism and estimates of LV dimensions. This seems to stand
in contrast with the recent report by Montgomery et al.
(20), who found that 10 weeks of training in military
recruits increased LV mass more in carriers of the D allele
than in those with the II genotype. However, in their study
those with II genotype had the largest hearts at baseline.
Our subjects had trained intensively for years, resulting in
marked adaptive hypertrophy, which could partly explain
the discrepancy between the studies. The reasons for the
conflicting results in the many earlier studies concerning
ACE genotypes and LV hypertrophy may involve differ-
ences and problems in genotyping assays, patient selection
and ethnic background. In harmony with earlier studies
(12,13), we did not find any association between LV
hypertrophy and AT1 A1166C polymorphism.
Possible mechanisms of genotype–phenotype associa-
tion. Recent studies point to the existence of local tissue
RAS in the heart and many other tissues (4–6), which may
function independently of the activity of the circulating
RAS and even contribute to myocardial cell growth. In vitro
and in vivo studies have suggested that mechanical stretch
up-regulates the expression of the local RAS genes in
cardiac myocytes, thereby initiating the positive feedback
mechanism in load-induced cardiac hypertrophy (4,5). Ex-
pression of the AGT gene is increased during hemodynamic
stress in rat’s heart (21) and by stretch in cultured cardiac
myocytes (4), creating conditions for an enhanced intracar-
diac angiotensin II formation. Angiotensin II has also been
shown to increase myocardial protein synthesis (22), to
promote cardiac myocyte growth (23) and to activate
specific intracellular signaling cascades that result in cardiac
hypertrophy (reviewed by Molkentin and Olson [24]). In
healthy young adults, plasma angiotensin II level is associ-
ated with the size of LV independently of blood pressure
(25). Collectively, all these data render the gene encoding
AGT a likely candidate for a genetic factor influencing
adaptive LV hypertrophy.
There is evidence that the concentration of AGT, instead
of that of ACE, has the limiting role in generation of
angiotensin II (6). Although there is no evidence that the
M235T polymorphism directly affects the function or se-
cretion of AGT, the concentration of AGT is about 13% to
20% higher in subjects carrying the 235T allele than in those
without it (6). M235T polymorphism has been shown to be
in linkage disequilibrium with a molecular variant in the
proximal promoter of the AGT gene affecting the basal
transcription rate of AGT (26), which also could explain the
increased AGT levels in subjects carrying the 235T allele.
Study limitations. We have no information of our athletes’
heart size in childhood before they adopted systematic and
long-lasting training, which is a limitation of this study.
Accordingly, there remains some uncertainty whether the
AGT M235T polymorphism influenced the basal LV mass,
or the exercise-induced increase in LV mass, or both.
However, in other studies no significant differences in
cardiac dimensions were found between different AGT
genotypes in healthy nonathletic subjects (9,11). We studied
only a limited number of athletes, and our results should be
confirmed in a larger study of individuals with adaptive
cardiac hypertrophy.
Conclusions. Our study provides evidence that variation in
the AGT gene locus associates with LV mass independently
of blood pressure in healthy individuals with adaptive
cardiac hypertrophy.
Reprint requests and correspondence: Dr. Jouko Karjalainen,
Central Military Hospital, Box 50, 00301 Helsinki, Finland.
E-mail: jouko.karjalainen@pp.inet.fi.
Table 4. Comparison of Athletes with Different AGT Genotypes
AGT Genotype
F pMM MT TT
Age (yr) 25.5 6 4.5 24.4 6 3.3 24.6 6 3.7 0.75 0.47
Height (cm) 177 6 9 176 6 9 177 6 7 0.12 0.89
BMI (kg/m2) 20.5 6 1.3 20.6 6 1.9 20.8 6 1.5 0.36 0.70
Training (h/week) 10.4 6 1.3 9.8 6 2.2 10.5 6 2.3 0.57 0.57
Systolic BP (mm Hg) 126 6 12 125 6 12 129 6 11 1.08 0.34
Diastolic BP (mm Hg) 77 6 11 74 6 9 72 6 9 1.93 0.15
LVEDD (mm) 53 6 4 53 6 4 54 6 3 1.32 0.27
LV posterior wall (mm) 10.3 6 1.0 10.4 6 1.6 11.0 6 1.3 4.06 0.021
E/A ratio 2.26 6 0.58 2.51 6 0.68 2.37 6 0.39 1.63 0.20
Values are adjusted for gender.
AGT 5 angiotensinogen; BMI 5 body mass index; BP 5 blood pressure; E/A 5 early peak flow velocity/peak atrial flow
velocity; LV 5 left ventricular; LVEDD 5 left ventricular end-diastolic diameter.
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